Harry Boxer
The Technical Trader
The stock market indices had a very tough, sloppy session and a mixed close. The day started out with a little pop to the upside, especially the S&P 500, and the Nasdaq 100 as well, but then they sold off very sharply on the Nasdaq 100, dropping back from 4309 to 4275. The S&P 500 had a much slighter pullback. Then they rallied into the afternoon, but, even though steady new highs were made on the S&P 500, including a new all-time high at 2086.73, the Nasdaq 100 couldn't get through 4290 on three occasions, chiefly because the large-cap biotech stocks on the Nasdaq 100 were hammered today. The biotech group as a whole had a very, very tough session. When the afternoon rally failed to break through at 4290 NDX, and confirmed the S&P 500 high, they then rolled over into the close.
Net on the day, the Dow finished at a new all-time high at 18,024.17, up 64.73, but traded about 45 points higher earlier in the day. The S&P 500 was up 3.73 at 2082.17, 4 points off the high. The Nasdaq 100 was down 14.37 at 4297.30, 5 points off the low and 30 points off the high.
Advance-declines were 20 to 11 on positive the New York Stock Exchange, but flat on Nasdaq. Up/down volume was 2 to 1 positive on New York, and traded just under 3 billion shares. Nasdaq traded 1.5 billion shares, and had a 4 to 3 negative volume ratio.
Most of that was because of the biotech stocks. For example, Agios Pharmaceuticals, Inc. (AGIO) dropped 13.56 to 107.22, Receptos, Inc. (RCPT) fell 18.43 to 118.00, Puma Biotechnology, Inc. (PBYI) gave back 20.17 to 189.84, Pharmacyclics Inc. (PCYC) closed down 12.13 to 120.69, ProShares and Ultra Nasdaq Biotechnology (BIB) caved 12.02 to 118.68.
Achillion Pharmaceuticals, Inc. (ACHN) was down 23.56 to 11.84, GW Pharmaceudtical (GWPH) down 4.06 to 66.26, BioDelivery Sciences International, Inc. (BDSI) down 1.44 to 11.99, NewLink Genetics Corporation (NLNK) 2.18 to 4.46, OvaScience, Inc. (OVAS) 4.89 to 40.51, Isis Pharmaceuticals, Inc. (ISIS) 5.27 to 57.61, PTC Therapeutics, Inc. (PTCT) 4.35 to 5to0.90, Auspex Pharmaceuticals, Inc. (ASPX) 4.33 50.03, just to mention a few of the biotech stocks, since many of those large-cap stocks were in the Nasdaq 100 stocks. That's why there was such a bad performance by Nasdaq 100 today.
Checking the TheTechTrader.com percent-gain leaderboard, there were some very good gainers today. Cytokinetics, Incorporated (CYTK) bounced 62 cents to 5.52, or 13%, on 1.3 million shares.
NQ Mobile Inc. (NQ), on a buyback plan, exploded to 4.77 before pulling back to 4.68, up 1.22, or 35%, on 3.6 million shares.
Vanda Pharmaceuticals, Inc. (VNDA), after regaining some drug rights, ran 1.67 to 13.58, or 14%, on 5.7 million shares. Herzfeld Caribbean Basin Fund Inc. (CUBA) is coming back again, up 1.78 to 14.12, or 14%, on 6 million shares.
Among other gainers, Momo Inc. (MOMO), a new issue, was up 1.14 to 11.97, Chesapeake Energy Corporation (CHK) up 1.87 to 20.29, Avis Budget Group, Inc. (CAR) 5.83 to 64.48, and Coherus Biosciences, Inc. (CHRS) 1.24 to 14.06, and was a standout today.
Stepping back and reviewing the hourly chart patterns, after a gap up, the indices pulled back, bounced midday, the S&P 500 continued to rally until midafternoon, but the Nasdaq 100 failed to confirm, and they rolled over to close mixed on the day.
Let's see what happens tomorrow.
In using any portion of The Technical Trader, you agree to the Terms and Conditions governing the use of the service as described in this disclaimer. Our disclaimers, policies and terms are subject to change without notice. The Technical Trader (www.thetechtrader.com) is published by Century-Pacific Investments and AdviceTrade, Inc., both of which are publishers. The Web site is maintained by Codexia, LLC. None of these firms, nor Mr. Boxer, is registered as a broker-dealer or investment adviser either with the U.S. Securities and Exchange Commission or with any state securities authority. Each trade mentioned in the diary and other sections of The Technical Trader is hypothetical and is not an actual trade. Mr. Boxer and employees of Century-Pacific, AdviceTrade and Codexia are not allowed to have personal positions in stocks mentioned in the diary and other sections of The Technical Trader. This policy, first announced to subscribers on June 2, 2004, gave Mr. Boxer a deadline that was extended to July 30, 2004 for liquidating any existing personal holdings in stocks mentioned on the site. Our holdings page, in which Mr. Boxer listed his personal positions in stocks mentioned on the site, was removed at that time. The publishers are not permitted to have any financial relationship with companies mentioned on the site. Mr. Boxer may recommend trades of stocks mentioned in the Diary as a consultant to hedge funds, but has agreed not to make such recommendations until after the stock has been posted on The Technical Trader Web site. Mr. Boxer's commentaries, trading ideas and model trades represent his own opinions and should not be relied upon for purposes of effecting securities transactions or other investing strategies, nor should they be construed as an offer or solicitation of an offer to sell or buy any security. You should not interpret Mr. Boxer's opinions as constituting investment advice. Neither we nor Mr. Boxer claim to have any non-public information regarding the companies mentioned in this site. The trade prices that appear on this Web site are based on the average of the real-time bid and real-time ask prices provided by Money.net, except when entered manually by Mr. Boxer should Money.net's feed be temporarily down. There may be a delay between the price as it appears in the diary and the current price that you see from your terminal due to delays in Internet connectivity, quote delays, refresh intervals in the case of the Web-based diary page, data entry errors, and market conditions, and also due to times when Mr. Boxer is not available to make the trade at the moment a previously stated target has been met. Entries may at times be in error due to system or data-entry errors. Hypothetical performance results do not include trading commissions and other execution costs that would be incurred if the trades referenced in the diary or elsewhere on the site were actual trades. Past performance is no guarantee of future results.
Recommended Content
Editors’ Picks
EUR/USD fluctuates near 1.0700 after US data
EUR/USD stays in a consolidation phase at around 1.0700 in the American session on Wednesday. The data from the US showed a strong increase in Durable Goods Orders, supporting the USD and making it difficult for the pair to gain traction.
USD/JPY refreshes 34-year high, attacks 155.00 as intervention risks loom
USD/JPY is renewing a multi-decade high, closing in on 155.00. Traders turn cautious on heightened risks of Japan's FX intervention. Broad US Dollar rebound aids the upside in the major. US Durable Goods data are next on tap.
Gold stays in consolidation above $2,300
Gold finds it difficult to stage a rebound midweek following Monday's sharp decline but manages to hold above $2,300. The benchmark 10-year US Treasury bond yield stays in the green above 4.6% after US data, not allowing the pair to turn north.
Worldcoin looks set for comeback despite Nvidia’s 22% crash Premium
Worldcoin price is in a better position than last week's and shows signs of a potential comeback. This development occurs amid the sharp decline in the valuation of the popular GPU manufacturer Nvidia.
Three fundamentals for the week: US GDP, BoJ and the Fed's favorite inflation gauge stand out Premium
While it is hard to predict when geopolitical news erupts, the level of tension is lower – allowing for key data to have its say. This week's US figures are set to shape the Federal Reserve's decision next week – and the Bank of Japan may struggle to halt the Yen's deterioration.